341 related articles for article (PubMed ID: 33488787)
1. The role of ixekizumab in non-radiographic axial spondyloarthritis.
San Koo B; Kim TH
Ther Adv Musculoskelet Dis; 2021; 13():1759720X20986734. PubMed ID: 33488787
[TBL] [Abstract][Full Text] [Related]
2. The role of ixekizumab in the treatment of nonradiographic axial spondyloarthritis.
Nam B; Kim TH
Immunotherapy; 2024 Mar; ():. PubMed ID: 38511247
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis.
Webers C; Ortolan A; Sepriano A; Falzon L; Baraliakos X; Landewé RBM; Ramiro S; van der Heijde D; Nikiphorou E
Ann Rheum Dis; 2023 Jan; 82(1):130-141. PubMed ID: 36270657
[TBL] [Abstract][Full Text] [Related]
4. Ixekizumab for treating ankylosing spondylitis.
Kiwalkar S; Beier S; Deodhar A
Immunotherapy; 2019 Oct; 11(15):1273-1282. PubMed ID: 31530049
[TBL] [Abstract][Full Text] [Related]
5. Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial.
Deodhar A; van der Heijde D; Gensler LS; Kim TH; Maksymowych WP; Østergaard M; Poddubnyy D; Marzo-Ortega H; Bessette L; Tomita T; Leung A; Hojnik M; Gallo G; Li X; Adams D; Carlier H; Sieper J;
Lancet; 2020 Jan; 395(10217):53-64. PubMed ID: 31813637
[TBL] [Abstract][Full Text] [Related]
6. Matching-Adjusted Indirect Comparison of the 52-Week Efficacy of Bimekizumab Versus Secukinumab and Ixekizumab for the Treatment of Radiographic Axial Spondyloarthritis.
Maksymowych WP; Thom H; Mørup MF; Taieb V; Willems D; Lyris N; Gaffney K
Rheumatol Ther; 2024 Jun; ():. PubMed ID: 38916823
[TBL] [Abstract][Full Text] [Related]
7. Ixekizumab: an IL-17A inhibitor for the treatment of axial Spondylarthritis.
Harrison SR; Marzo-Ortega H
Expert Rev Clin Immunol; 2021 Oct; 17(10):1059-1071. PubMed ID: 34407705
[TBL] [Abstract][Full Text] [Related]
8. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial.
van der Heijde D; Cheng-Chung Wei J; Dougados M; Mease P; Deodhar A; Maksymowych WP; Van den Bosch F; Sieper J; Tomita T; Landewé R; Zhao F; Krishnan E; Adams DH; Pangallo B; Carlier H;
Lancet; 2018 Dec; 392(10163):2441-2451. PubMed ID: 30360964
[TBL] [Abstract][Full Text] [Related]
9. Different drug survival of first line tumour necrosis factor inhibitors in radiographic and non-radiographic axial spondyloarthritis: a multicentre retrospective survey.
Lopalco G; Venerito V; Cantarini L; Emmi G; Salaffi F; Di Carlo M; Tafuri S; Gentileschi S; Di Scala G; Nivuori M; Cacciapaglia F; Galeazzi M; Lapadula G; Iannone F
Clin Exp Rheumatol; 2019; 37(5):762-767. PubMed ID: 31025925
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST.
Braun J; Kiltz U; Deodhar A; Tomita T; Dougados M; Bolce R; Sandoval D; Lin CY; Walsh J
RMD Open; 2022 Jul; 8(2):. PubMed ID: 35853675
[TBL] [Abstract][Full Text] [Related]
11. Ixekizumab improves spinal pain, function, fatigue, stiffness, and sleep in radiographic axial Spondyloarthritis: COAST-V/W 52-week results.
Deodhar AA; Mease PJ; Rahman P; Navarro-Compán V; Strand V; Hunter T; Bolce R; Leon L; Lauzon S; Marzo-Ortega H
BMC Rheumatol; 2021 Sep; 5(1):35. PubMed ID: 34538257
[TBL] [Abstract][Full Text] [Related]
12. Secukinumab in axial spondyloarthritis: a narrative review of clinical evidence.
Braun J; Kiltz U; Bühring B; Baraliakos X
Ther Adv Musculoskelet Dis; 2021; 13():1759720X211041854. PubMed ID: 34471428
[TBL] [Abstract][Full Text] [Related]
13. Ixekizumab improves sleep and work productivity in patients with non-radiographic axial spondyloarthritis: results from the COAST-X trial at 52 weeks.
Deodhar A; Mease P; Marzo-Ortega H; Hunter T; Sandoval D; Kronbergs A; Lauzon S; Leung A; Navarro-Compán V
BMC Rheumatol; 2021 Sep; 5(1):50. PubMed ID: 34560906
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials.
van der Heijde D; Deodhar A; Baraliakos X; Brown MA; Dobashi H; Dougados M; Elewaut D; Ellis AM; Fleurinck C; Gaffney K; Gensler LS; Haroon N; Magrey M; Maksymowych WP; Marten A; Massow U; Oortgiesen M; Poddubnyy D; Rudwaleit M; Shepherd-Smith J; Tomita T; Van den Bosch F; Vaux T; Xu H
Ann Rheum Dis; 2023 Apr; 82(4):515-526. PubMed ID: 36649967
[TBL] [Abstract][Full Text] [Related]
15. IL-17 inhibition in axial spondyloarthritis: current and future perspectives.
Torgutalp M; Poddubnyy D
Expert Opin Biol Ther; 2019 Jul; 19(7):631-641. PubMed ID: 30957574
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W).
Dougados M; Wei JC; Landewé R; Sieper J; Baraliakos X; Van den Bosch F; Maksymowych WP; Ermann J; Walsh JA; Tomita T; Deodhar A; van der Heijde D; Li X; Zhao F; Bertram CC; Gallo G; Carlier H; Gensler LS;
Ann Rheum Dis; 2020 Feb; 79(2):176-185. PubMed ID: 31685553
[TBL] [Abstract][Full Text] [Related]
17. Ixekizumab Improves Patient-Reported Outcomes in Non-Radiographic Axial Spondyloarthritis: Results from the Coast-X Trial.
Deodhar A; Mease P; Rahman P; Navarro-Compán V; Marzo-Ortega H; Hunter T; Sandoval D; Kronbergs A; Leon L; Shan M; Leung A; De Vlam K; Strand V
Rheumatol Ther; 2021 Mar; 8(1):135-150. PubMed ID: 33284423
[TBL] [Abstract][Full Text] [Related]
18. Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis: Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry.
Glintborg B; Sørensen IJ; Østergaard M; Dreyer L; Mohamoud AA; Krogh NS; Hendricks O; Andersen LS; Raun JL; Kowalski MR; Danielsen L; Pelck R; Nordin H; Pedersen JK; Kraus DG; Christensen SR; Hansen IM; Esbesen J; Schlemmer A; Loft AG; Al Chaer N; Salomonsen L; Hetland ML
J Rheumatol; 2017 Jan; 44(1):59-69. PubMed ID: 27909080
[TBL] [Abstract][Full Text] [Related]
19. Emerging Immunomodulatory Therapies and New Treatment Paradigms for Axial Spondyloarthritis.
Mease P
Curr Rheumatol Rep; 2019 Jun; 21(7):35. PubMed ID: 31172311
[TBL] [Abstract][Full Text] [Related]
20. The cost-effectiveness of a bimekizumab versus IL-17A inhibitors treatment-pathway in patients with active axial spondyloarthritis in Scotland.
Mørup MF; Taieb V; Willems D; Rose M; Lyris N; Lamotte M; Gerlier L; Thom H
J Med Econ; 2024; 27(1):682-696. PubMed ID: 38650583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
